← All trials
NCT04630067
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 17, 2020
- Primary completion
- Nov 18, 2021
- Completion date
- Nov 18, 2021
- First posted
- Nov 16, 2020
- Last posted
- Nov 30, 2020
- Enrollment
- 104
- Arms / groups
- 12 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AstraZenecaLead sponsor
- Henry Ford Health SystemOverall official - principal investigator
- ParexelOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.